Advertisements

Olicard retard

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Olicard retard

Olicard retard is an extended-release preparation for oral use containing Isosorbide Mononitrate. It is classified as an antianginal drug that works by widening blood vessels to optimize oxygen supply and reduce the heart's workload. As a prescription-only medicine, its use is managed by healthcare professionals.


Quick Facts Overview

Property Description
Active ingredient Isosorbide Mononitrate
Form Extended-release (Retard) capsule or tablet
Pharmacological class Organic Nitrate, Vasodilator
Origin Synthetic compound
Differentiating Feature Sustained-release for once-daily prophylactic use

Olicard retard: Identity and Pharmacological Class

The active substance in Olicard retard is Isosorbide Mononitrate, a synthetic compound belonging to the pharmacological group known as organic nitrates. Its primary action is that of a vasodilator, meaning it relaxes the smooth muscle within the walls of arteries and veins, causing them to expand. This function is clinically recognized for its ability to reduce vascular resistance and improve blood flow. Isosorbide Mononitrate is a nitrate medicine that works by relaxing blood vessels, which decreases the amount of work the heart has to do.

Understanding the Extended-Release (Retard) Dosage Form

A key defining feature of Olicard retard is its sustained-release dosage form, which is a type of modified-release delivery system. The term 'retard' emphasizes that the active ingredient is released and absorbed slowly and consistently over a long period, contrasting with immediate-release forms of the same drug. This characteristic makes Olicard retard a long-acting preparation, providing continuous, daily prophylactic support.

General Purpose as an Antianginal Agent

Olicard retard is primarily utilized for its antianginal properties, supporting the cardiovascular system by improving circulation. Its general purpose is to provide steady support, often for individuals requiring continuous pharmacological management. By acting as a coronary vasodilator, the medicine increases blood flow to the heart, and by widening other vessels, it reduces the pressure against which the heart pumps. This dual mechanism ensures that the heart receives sufficient oxygen supply and operates with less strain.

Regulatory References

  1. Isosorbide Mononitrate - MedlinePlus
  2. MedlinePlus: Isosorbide Mononitrate
Advertisements

What side effects are possible with Olicard retard?

Possible Side Effects and Safety Information

Olicard retard, which contains Isosorbide Mononitrate, has a documented safety profile organized by the drug's primary action as a vasodilator, according to official regulatory labeling. Adverse reactions are classified by their frequency and the system-organ class affected.


Adverse Reactions by Frequency

Adverse effects are often dose-dependent and most pronounced early in treatment. The most common effects are linked to the Nervous System and Vascular Systems:

  • Very Common (ge 1/10): Headache, which is frequently transient and tends to resolve with continued use.
  • Common (ge 1/100 to <1/10): Dizziness, Hypotension (low blood pressure), Tachycardia (fast heart rate), and Nausea.
  • Uncommon (ge 1/1,000 to <1/100): Vomiting and Diarrhea.
  • Rare (ge 1/10,000 to <1/1,000): Syncope (fainting), Rash, and Pruritus (itching).

Serious Safety Considerations

The label documents that severe Hypotension may lead to an exacerbation of angina pectoris symptoms. A rare but serious blood disorder, Methaemoglobinaemia, is also noted.

Safety Patterns and Constraints

Adverse effects, particularly headache and hypotension, are most likely to occur at the initiation of treatment and often lessen as therapy continues. The risk of tolerance developing to the antianginal effects with chronic, continuous exposure is also specified. A critical safety constraint is the strict contraindication with Phosphodiesterase Type 5 (PDE-5) inhibitors (such as sildenafil), which can lead to life-threatening severe hypotension. Official documents also note that older adults may be more sensitive to hypotensive effects.

Advertisements

Overdose and Emergency Response

The official regulatory profile for Olicard retard overdose, based on governmental labeling, focuses on the clinical manifestations resulting from severe vasodilation. Documented presentations include profound hypotension, persistent, pulsating headache, flushing, palpitations, visual disturbances, nausea, and vomiting. These effects impact the cardiovascular, central nervous, and hematological systems.

More severe outcomes noted in official labeling include syncope, bradycardia, and the life-threatening condition Methaemoglobinaemia, particularly associated with high-dose or massive overdose. Ischemia and sudden death are listed as potential severe complications.

When such severe manifestations occur, immediate medical attention and hospital monitoring are required. Treatment is generally symptomatic and supportive. For marked hypotension, official guidance mandates placing the patient in the supine position with the legs raised and administering intravenous fluids. The use of a vasopressor is reserved only for cases where fluid resuscitation fails to correct the hypotension. Intravenous Methylene Blue is documented as the specific antidote for severe Methaemoglobinaemia.

Advertisements

Therapeutic Uses of Olicard retard

What Olicard Retard Treats: Main Uses and Benefits

Olicard retard is primarily utilized in the long-term prophylactic management of Angina Pectoris, a condition arising from Coronary Artery Disease. This medication is relevant in the therapeutic domains of chronic stable angina and for adjunctive support in certain forms of heart failure. This medicine is generally used for the management of chest pain but is not suitable for treating an acute episode that has already begun.

It is applied to address symptom patterns characteristic of recurrent chest discomfort, including episodes triggered by physical exertion (effort angina) and those occurring during rest. By providing continuous, sustained support, it may assist with easing the overall symptomatic burden that interferes with daily functioning. Its primary relevance is for managing chronic symptoms, rather than for addressing sudden, isolated manifestations. This supportive relief generally contributes to better functional stability and helps patients cope more steadily with symptom fluctuations, thereby supporting the maintenance of a sense of stability during routine activities.

Quick Fact: Relief for Recurrent Chest Discomfort

Regulatory References

  1. NIH MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

Olicard retard contains isosorbide mononitrate (extended-release), and its eligibility profile is strictly defined by government regulatory documents based on contraindications and patient risk factors.

Classification Population/Condition Restriction
Absolute Contraindication Patients taking PDE5 inhibitors (e.g., sildenafil, tadalafil) or riociguat. Must not use (Risk of severe hypotension).
Absolute Contraindication Patients with known hypersensitivity to any organic nitrate or formulation component. Must not use (Risk of allergic reaction).
Conditional Use Patients who are hypotensive, volume depleted, or have hypertrophic cardiomyopathy. Use with caution (Risk of severe or worsened low blood pressure/angina).
Conditional Use Elderly patients Use with caution (Increased susceptibility to orthostatic hypotension).
Use Not Established Pediatric patients (under 18 years) Safety and effectiveness not established.
Lactation Status Nursing mothers Use with caution (Unknown if drug is excreted in human milk).

The drug is also not recommended for aborting an acute anginal episode due to its slow onset of action. All restrictions are based solely on official labeling for the active substance.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Olicard retard (Isosorbide Mononitrate extended-release) is governed by specific regulatory restrictions and documented pharmacodynamic effects. Co-administration with certain substances is officially classified as a contraindication due to the risk of severe, life-threatening hypotension.


Contraindicated Combinations

The use of Olicard retard is strictly prohibited with Phosphodiesterase Type 5 (PDE5) Inhibitors (e.g., sildenafil, tadalafil, vardenafil) and Soluble Guanylate Cyclase (sGC) Stimulators (e.g., riociguat). These combinations carry a significant, officially documented risk of potentiating the vasodilatory effect, which may lead to circulatory collapse.


Pharmacodynamic and Exposure Effects

The drug’s blood pressure-lowering effect may be potentiated when co-administered with alcohol or other antihypertensive medicines (including ACE inhibitors, beta-blockers, and calcium channel blockers). Furthermore, the official prescribing information notes that Olicard retard can increase the blood level of Dihydroergotamine, which may amplify its associated hypertensive effect. Regarding consumption, administration of the extended-release formulation with a high-fat meal has been shown to increase the drug’s overall exposure ( AUC and C max). These are the formally documented interaction patterns established in regulatory sources.

Advertisements

Mechanism of Action

How Olicard retard Works: The Mechanism of Action

The mechanism of Isosorbide Mononitrate (Olicard retard) is defined by its core action as a nitric oxide donor that triggers a cascade of smooth muscle relaxation throughout the circulatory system.


Molecular Activation of the cGMP Pathway

The drug functions as a source of Nitric Oxide (NO) within the blood vessel walls. This NO activates the enzyme soluble Guanylyl Cyclase (sGC), resulting in a crucial increase of the cellular messenger cyclic Guanosine Monophosphate (cGMP). This cascade leads directly to the core cellular effect: the relaxation of vascular smooth muscle cells.


Regulation of Systemic Preload and Vasodilation

This mechanistic domain focuses on the system-level consequences of smooth muscle relaxation. The induced vasodilation is most pronounced in the veins (capacitance vessels), causing blood pooling that reduces the volume and pressure of blood returning to the heart (Preload). This physiological adjustment is linked to a reduction in myocardial wall tension and cardiac oxygen demand.


Mechanistic Constraint: The Phenomenon of Nitrate Tolerance

Continuous, high-level exposure to the molecule can lead to Nitrate Tolerance, a state where the vasodilatory mechanism is significantly weakened or exhausted. This physiological constraint requires the mechanism to operate under intermittent conditions to restore full biological responsiveness.

Advertisements

Dosage and Administration Information

How to Use Olicard retard — Administration Guidelines

This section outlines the administration instructions for Olicard retard (Isosorbide Mononitrate Extended-Release).


Administration Scope

Item Detail
Route of Administration Oral (swallowed by mouth).
Dosing Schedule Typically once daily (QD), taken in the morning. The initial dose is often 30 mg or 60 mg, which may be titrated as directed by a healthcare provider.
Timing in Relation to Meals May be taken with or without food.
Preparation Requirements None. The formulation is extended-release.

Procedural and Dosing Constraints

The extended-release capsule or tablet must be swallowed whole with an adequate amount of fluid. It is an explicit instruction that the medicine must not be crushed, chewed, or divided, as this action destroys the extended-release mechanism, leading to rapid drug release.

The dosing schedule is specifically designed for a once-daily intake to ensure a daily drug-free interval, which is essential for maintaining the medicine’s effectiveness over long-term use. This scheduled break is a key component of the administration protocol.


Population-Specific Rules

Patient Group Instruction
Geriatric Patients No routine dose adjustment is typically required based on age alone.
Pediatric Use Safety and effectiveness in pediatric patients have not been established.

Missed-Dose Rules: If a dose is missed, take it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. Do not double the dose to make up for a missed one.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of Studies for Olicard Retard

Evidence for Use in Chronic Stable Angina Pectoris

The research base for the extended-release formulation of Isosorbide Mononitrate primarily involves Randomized Controlled Trials (RCTs). These studies were used to understand the medicine’s clinical profile relevant to the use intended for prevention of recurrent episodes in individuals with angina pectoris, a condition characterized by fluctuating or episodic manifestations of chest discomfort. Researchers was evaluated in adults diagnosed with stable chest pain due to confirmed Coronary Artery Disease.

Studies reported measurements where the administration of the medicine was associated with patterns such as measurements of longer exercise tolerance times when compared to placebo measurements in the observed populations. Trials described patterns where the self-reported anginal attack frequency evolved over the intermediate observation periods. Research protocols were designed to address the phenomenon called nitrate tolerance, where the body's response to continuous exposure can lessen over time.

Evidence for Use as Adjunctive Support in Heart Failure

The medicine was studied for its use as an adjunctive support alongside standard therapy in individuals with certain types of heart failure. Researchers examined endpoints such as exercise capacity, daily activity levels, and changes in certain biomarkers. The findings were mixed across studies examining the medicine in the context of heart failure. Some research described changes observed during the study period, while other trials reported patterns where certain outcomes were not different from the placebo measurements.

What remains uncertain relates to the overall contribution of these findings. The evidence is derived mostly from studies focused on surrogate endpoints, and comparative evidence is lacking for the medicine’s long-term impact on major events like hospitalizations in this population.

What Remains Uncertain in the Research Landscape

Several limitations are acknowledged in the scientific documentation. The research generally focuses on outcomes related to physical discomfort and exercise capability rather than on long-term prevention of major cardiovascular complications. Therefore, long-term effects are not fully established regarding mortality or heart attack rates. Furthermore, the evidence quality varies across studies, and the data for certain groups remain insufficient.

Key Studies & References

  1. Nitrates in Congestive Heart Failure (NICE) Study: Effect of isosorbide-5-mononitrate on exercise performance
  2. Isosorbide Mononitrate Extended-Release Tablets, USP Prescribing Information (DailyMed/FDA Label)
  3. Stable angina: management (NICE guideline CG126)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Olicard retard (FAQ)


Q: Is Olicard retard the same type of medicine as regular Olicard?

The 'retard' or extended-release formulation and the regular (immediate-release) form both contain the same active ingredient, isosorbide mononitrate. The key difference is in how the medicine is delivered: the 'retard' form is specially manufactured to release the substance gradually over a much longer time to ensure sustained effectiveness.


Q: Why is this medicine called 'retard'?

The term 'retard' is a descriptive word used in some countries to indicate a medicine that has a prolonged or slow-release mechanism. This means the medicine is designed to release its active substance slowly throughout the day, providing a sustained effect.


Q: What is the duration of effect of Olicard retard?

According to official product information, the extended-release formulation is designed to provide a therapeutic effect for at least 12 hours. This sustained action is necessary to ensure effectiveness while maintaining the essential daily drug-free interval required by nitrate therapy.


Q: Do people develop a tolerance to the effects of Olicard retard over time?

Regulatory documents acknowledge that tolerance to nitrate effects can occur with chronic, continuous exposure. The drug's official dosing schedule is designed to incorporate a period each day when the drug level is low (a drug-free interval), which is necessary to help prevent tolerance.


Q: What is the difference between Olicard retard and isosorbide dinitrate?

Olicard retard contains isosorbide mononitrate, which is a key active breakdown product, or metabolite, of isosorbide dinitrate. Because of its chemical structure, the mononitrate form has a high and predictable availability in the body, which is a difference from the dinitrate form.


Q: Is there any research on Olicard retard use in children or teenagers?

Official labeling states that the safety and effectiveness of this medicine in pediatric patients (children and teenagers) have not been established in appropriate studies.


Q: Can I take Olicard retard if I have low blood pressure?

This medicine is noted to be a vasodilator, meaning it opens blood vessels and can cause low blood pressure (hypotension). Regulatory warnings state that caution should be exercised with patients who are volume-depleted or who already have hypotension.


Q: What does official guidance say about Olicard retard use during acute heart events?

Official indications clearly state that Olicard retard is for the prevention and long-term management of chest pain. Its onset of action is not rapid enough for the medicine to be useful in aborting an acute anginal episode.


Q: Is it common for doctors to combine Olicard retard with aspirin?

Official interaction documents do not prohibit the co-administration of this medicine with common over-the-counter pain relievers, such as aspirin or acetaminophen. The labels note these pain relievers can often be used to manage the headaches sometimes associated with starting nitrate treatment.


Q: Does Olicard retard change my heart rate?

Changes in heart rate are documented in the official safety information. Tachycardia (fast heart rate) is listed as a common side effect. In rare cases of severe low blood pressure, the drug's effect may also be associated with bradycardia (slow heart rate).


Q: Does Olicard retard help prevent chest pain in the long run?

Regulatory documents indicate that the medicine is specifically intended for the long-term management and prevention of angina pectoris, which is recurrent chest pain due to coronary artery disease.


Q: How quickly does Olicard retard start working after I take it?

The onset of effect for the extended-release form is not immediate. Clinical pharmacology data indicate that the therapeutic effect typically begins approximately 30 to 45 minutes after the dose is taken.


Q: Are there any common foods or drinks to avoid while taking Olicard retard?

Regulatory information notes the potential for the blood pressure-lowering effect to be enhanced by alcohol. Beyond this, there are no specific foods or drinks listed in regulatory warnings that significantly alter the drug's effect.


Q: Do older adults typically use Olicard retard for heart issues?

The medicine is commonly used by adults, including older adults, and no routine dose adjustment is required based on age alone. However, official warnings advise that older patients may be more sensitive to hypotensive effects.


Q: What kind of studies support the use of Olicard retard?

The clinical profile is supported by controlled studies, such as randomized controlled trials. These trials measured the medicine's effect on functional outcomes, specifically assessing how it improved exercise tolerance and time to the onset of angina symptoms compared to a placebo.


Q: Can Olicard retard be used by people with kidney problems?

Renal clearance (elimination through the kidneys) is only a minor route for the elimination of the drug from the body. While specific dose adjustments are not generally required, caution is advised for patients with existing severe kidney problems.


Q: Is Olicard retard used for conditions other than heart pain?

Official indications primarily focus on the prevention of angina pectoris. However, the medicine has also been examined as an adjunctive support therapy alongside standard treatment for certain types of heart failure.


Q: What are the serious but rare side effects associated with Olicard retard?

Serious, but rare, documented effects include severe hypotension (very low blood pressure) and syncope (fainting). A rare but potentially serious blood disorder called methemoglobinemia is also noted in official safety information.


Q: Has Olicard retard been recalled or had any major safety warnings issued?

Regulatory agencies continually monitor the safety of all marketed products. Official notices often address supply issues, but the drug’s labeling continually outlines specific safety warnings that remain in effect, such as the strict contraindication with PDE-5 inhibitors.


Q: Does Olicard retard help with high cholesterol?

The medicine is not indicated for the treatment of high cholesterol. Official documents mention that nitrates may interfere with a specific chemical process, which could potentially cause falsely low readings in some types of laboratory serum cholesterol tests.


Q: Can Olicard retard cause skin rash or allergic reactions?

Rare side effects, according to official information, include skin rash and pruritus (itching). Allergic reactions, including swelling of the face and hives, are also noted in safety information.


Q: What is the typical age range of people using Olicard retard?

The medicine is indicated for use in adults. Specific age ranges are not defined, but official information notes that its safety and efficacy are not established in pediatric patients, and older patients may have an increased sensitivity to its effects.


Q: Are there different strengths of Olicard retard available?

Yes, official documents on the dosage forms and strengths indicate that extended-release tablets containing the active ingredient are commonly available in multiple strengths, such as 30 mg, 60 mg, and 120 mg.


Q: Why is Olicard retard only available in a slow-release form?

The slow-release formulation is utilized primarily because it maintains effective drug levels over a 24-hour period. This design also facilitates the necessary daily drug-free interval that is crucial for preventing the development of nitrate tolerance.


Q: What if I have an existing lung condition like asthma—can I still use Olicard retard?

The official label documents asthma as a rare adverse event and increased cough as a side effect. Official information indicates that a discussion with a healthcare provider regarding pre-existing conditions is necessary.


Q: Does Olicard retard affect vision?

Official safety information lists blurred vision as a documented side effect, often linked to episodes of low blood pressure. Rare ocular effects like Amblyopia have also been reported.


Q: Is it normal to feel tired when first starting Olicard retard?

Fatigue is listed as a reported side effect that may be experienced when taking the medicine, according to official adverse reaction lists.


Q: Can Olicard retard be stopped suddenly, or does it require gradual reduction?

Regulatory documents advise against changing the schedule or stopping the medicine without consulting a healthcare provider. Sudden withdrawal in patients with high nitrate exposure (such as industrial workers) has been associated with acute heart events.

Advertisements

How should Olicard retard be stored and disposed of?

Storage Conditions

Olicard retard must be stored in the original package at a temperature below 25 C or at controlled room temperature, which is often specified as between 15 C and 30 C (mathbf59 F and mathbf86 F). The container should be kept tightly closed and protected from excessive moisture and heat. The medication must be kept out of the sight and reach of children.

Prohibited Environments and Stability

It is mandatory not to store the product in the bathroom due to humidity and not to refrigerate or freeze it. The medicine must not be used past the expiry date printed on the packaging, as stability is not guaranteed after this time.

Disposal Instructions

Any unused or expired Olicard retard must not be disposed of via household waste or by flushing down the toilet. The product must be discarded according to local requirements, typically by utilizing a pharmaceutical take-back program or returning it to a pharmacy.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Olicard retard found in:

A-Z Index: